BioNTech extends COVID vaccine trials in China

Vaccine developer BioNTech has extended the second phase of clinical trials of its COVID-19 vaccine in China by six months until October, a registry of such trials showed. The vaccine is one of the most widely used in the world against COVID but has yet to be approved in China.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner